USMAN NASSIM
Known title: President & CEOCIK: 0001206872
USMAN NASSIM's purchase track record
USMAN NASSIM has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/9/2022 | GYRE | $2K | +12.3% | -6.0% | +1.0% |
| 2/9/2022 | GYRE | $1K | -32.7% | +236.4% | -8.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| GYRE | ▲ Buy | Option Exercise | 3,452 | $24K | 6/28/2024 | View on chart |
| GYRE | ▼ Sell | Open Market | 3,452 | $41K | 6/28/2024 | View on chart |
| GYRE | ▲ Buy | Option Exercise | 20,000 | $139K | 5/1/2024 | View on chart |
| GYRE | ▼ Sell | Open Market | 5,000 | $75K | 5/1/2024 | View on chart |
| GYRE | ▼ Sell | Open Market | 100 | $2K | 5/1/2024 | View on chart |
| GYRE | ▼ Sell | Open Market | 14,900 | $207K | 5/1/2024 | View on chart |
| GYRE | ▲ Buy | Option Exercise | 20,000 | $139K | 4/1/2024 | View on chart |
| GYRE | ▼ Sell | Open Market | 20,000 | $323K | 4/1/2024 | View on chart |
| GYRE | ▲ Buy | Option Exercise | 20,000 | $139K | 3/15/2024 | View on chart |
| GYRE | ▼ Sell | Open Market | 20,000 | $345K | 3/15/2024 | View on chart |
| GYRE | ▼ Sell | Other | 8 | — | 8/31/2023 | View on chart |
| GYRE | ▼ Sell | Other | 1 | — | 8/31/2023 | View on chart |
| GYRE | ▼ Sell | Other | 25 | — | 8/31/2023 | View on chart |
| GYRE | ▲ Buy | Open Market | 3,250 | $2K | 8/9/2022 | View on chart |
| GYRE | ▲ Buy | Open Market | 3,250 | $1K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Gyre Therapeutics Schedules Investor Meetings for September
Gyre Therapeutics has announced participation in upcoming investor conferences scheduled for September. The company will engage with institutional investors and analysts through these scheduled meetings. Shares are currently trading near established support at $6.32, within a 52-week range of $5.44 to $9.42. Three analysts currently maintain an average price target of $18.67.
Gyre Therapeutics Schedules Investor Meetings for September. Gyre Therapeutics has announced participation in upcoming investor conferences scheduled for September. The company will engage with institutional investors and analysts through these scheduled meetings. Shares are currently trading near established support at $6.32, within a 52-week range of $5.44 to $9.42. Three analysts currently maintain an average price target of $18.67.